Biosimilars Potential Benefits

How do biosimilars offer a potential for greater savings and access across the health care system?

Addressing the challenges of the current US pharmaceutical landscape
In Just 5 Years, Originator Biologics Were Granted 77 New Approvals (2015-2020)

In just 5 years, originator biologics were granted

77 new approvals1


And biologic products account for

43% of all US medicine spending2


Could biosimilars help reduce costs to the health care system and help with patient access to biologics?

Evolving the health care system to meet increasing demands

How generics did it

In 1984, Congress established the Drug Price Competition and Patent Term Restoration Act ("Hatch-Waxman") to encourage competition and provide incentives for pharmaceutical innovators to develop new drugs.4 The influence of Hatch-Waxman wasn’t felt overnight.5 Working together now, we may help make an impact with biosimilars sooner.

What generics were to the US health care system in the 20th century is what biosimilars have the potential to become in the 21st century.5

Generic Makes Up 90% of Today's Share of US Prescriptions
Generic share of US prescriptions by year3, 5
Why biosimilars are being introduced—to help reduce biologic costs6

Through the adoption of biosimilars, it is estimated that the health care system could save

$104 BILLION from 2020 to 2024.2

Through the Adoption of Biosimilars it Is Estimated the Health Care System Could Save $104 Billion From 2020 to 2024

As competition increases from biosimilar adoptions, the potential for significant savings to the health care system increases as well.7

Maintaining the balance between innovation and accessibility

Congress passed the Biologics Price Competition and Innovation Act (BPCIA) of 2009 with the goals of 8,9:

Facilitating Biosimilar Competition

Facilitating biosimilar competition

By establishing a pathway to approval

Reducing Health Care Costs By Potentially Lowering the Overall Costs of Biologics Through the Introduction of Biosimilars

Reducing health care costs

By potentially lowering the overall costs of biologics through the introduction of biosimilars

Increasing Options By Offering Greater Access to Medications and By Expanding Payer, Provider, and Patient Choice

Increasing options

  • By offering greater access to medications
  • By expanding payer, provider, and patient choice

US Department of Health and Human Services (HHS) is taking steps to help address the challenges of access to and reimbursement of biosimilars, such as10:

  • Improving billing and payment code policies under Medicare Part B
  • Revising Medicare Part C and D regulations to help increase access to biosimilars
In Just 5 Years, Originator Biologics Were Granted 77 New Approvals (2015-2020)

FDA’s Biosimilars Action Plan8

The FDA has laid out a multifaceted action plan to foster biologic innovation and further biosimilars development. Key measures range from the development and implementation of new FDA review tools to providing revised guidance on biosimilar topics and the establishment of a new Office of Therapeutic Biologics and Biosimilars (OTBB).

Governmental entities are actively engaged in helping to improve adoption of biosimilars across the US health care system.8,9

The future looks bright

When stakeholders throughout the health care system come together to achieve mutually beneficial goals, great things can happen. Biosimilar adoption could help lay the groundwork for future generations of breakthrough treatments.
Biosimilar Adoption Could Help Lay the Groundwork For Future Generations of Breakthrough Treatments

Want more in-depth biosimilar education?

Biosimilars Overview

Interactive educational resource for anyone interested in understanding the biosimilars landscape.

Biosimilars Question and Answer Guide

Guide that explains what biosimilar medicines are, how they compare to originator biologics, and how they are approved.

Get Familiar with Biosimilars

One-minute video introducing biosimilars, their purpose, and potential impact.

Get Familiar with Biosimilars

FDA, US Food and Drug Administration.

References: 1. Center for Drug Evaluation and Research. List of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to date. September 9, 2014. Updated August 3, 2020. Accessed November 2, 2022. 2. Aitken M, Kleinrock M, Muñoz E. Biosimilars in the United States 2020–2024: competition, savings, and sustainability. IQVIA Institute for Human Data Science report. September 29, 2020. Accessed November 2, 2022. 3. Association for Accessible Medicines. Securing our access & savings: 2020 generic drug & biosimilars access & savings in the U.S. report. Accessed November 2, 2022. 4. Blackstone EA, Fuhr JP Jr. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–478. 5. US Food and Drug Administration. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s biosimilars action plan. July 18, 2018. Accessed November 2, 2022. 6. US Food and Drug Administration. Biosimilars drop-in articles. October 19, 2017. Accessed November 2, 2022. 7. Mulcahy AW, Hlávka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Accessed November 2, 2022. 8. US Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. July 2018. Accessed November 2, 2022. 9. US Food and Drug Administration. From our perspective: biosimilar product labeling. Updated July 18, 2018. Accessed November 2, 2022. 10. US Department of Health & Human Services. American patients first: the Trump administration blueprint to lower drug prices and reduce out-of-pocket costs. May 2018. Accessed November 2, 2022.